Australian ADHD Panel Said To Have Members With Drug Firm Ties
This article was originally published in PharmAsia News
Executive Summary
An Australian newspaper says physicians and others serving on a panel that sets ADHD treatment guidelines have financial connections to several large drug makers. The Daily Telegraph identified seven of the 10 members of the guideline-setting committee who it said received funds or financial help from drug makers such as Eli Lilly, Celltech and Shire Pharmaceuticals, all makers of ADHD drugs the panel was considering. Among the advice in the guidelines is a warning to ignore alternative treatments, such as diet and exercise, on grounds there is little evidence they are effective. (Click here for more
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.